Market Research report comprising epidemiology data, FDA approvals & patent expirations, market dynamics (drivers, unmet needs, barriers) along with market size and forecast of current marketed drugs and Phase 3 & NDA-filed pipeline drugs. This report also covers geographic (regional) market segmentation, market share of key players, mapping of pipeline (Preclinical to Phase 3) and profiling of major companies in this market.

1. Antacids Market - Global Marketed and Pipeline Drugs
Analysis and Forecast - 2015 to 2025
http://www.xcelsioranalytics.com
info@xcelsioranalytics.com
Table of Contents and Report Description
Antacids market, comprising epidemiology data, FDA approvals & patent expirations, market
dynamics (drivers, unmet needs, barriers) along with market size and forecast of current
marketed drugs and Phase 3 & NDA-filed pipeline drugs. This report also covers geographic
(regional) market segmentation, market share of key players, mapping of pipeline (Preclinical to
Phase 3) and profiling of major companies in this market.
Section Description
Section 1:
Introduction Board
An interactive interface for graphical and tabular destination to any
section of the Antacids market report.
Section 2:
Epidemiology
Qualitative analysis of the epidemiology data (causes, signs,
symptoms and currently available treatments) for Antacids along with
worldwide prevalence data of major indications treated by Antacids
(forecasted till 2025).
Section 3:
FDA Approvals and
Patent Expirations
Tabular representation of all the FDA approvals and expected patent
expirations of marketed Antacids along with expected FDA approval
dates of Phase 3 and NDA-filed pipeline Antacids.
Section 4:
Market Dynamics
and Principal
Unmet Needs
Description of principal unmet needs in the Antacids market coupled
with the top indicators that are driving and restraining the market
growth.

2. Section 5:
Market Size and
Forecast – Total
Drugs and
Marketed Drugs
 Quantitative Analysis of total drugs market and top marketed
Antacids (estimated market size and forecast in USD million) for
the period 2015 to 2025.
 Qualitative Analysis (patent expiry effects, influence of pipeline
drugs, patient and physician preference) for the current marketed
drugs in the Antacids market.
Section 6:
Market Size and
Forecast - Phase 3
and NDA-filed
Pipeline Drugs
 Quantitative Analysis of Phase 3 and NDA-filed pipeline Antacids
(estimated market size and forecast in USD million) for the period
2015 to 2025.
 Qualitative Analysis of Phase 3 and NDA-filed pipeline drugs
(expected physician prescribing pattern and patient preference,
competition with current marketed drugs) for the Antacids market.
Section 7:
Market Size and
Forecast – Market
by Major
Indications
Quantitative and qualitative analysis of major indications treated by
Antacids (estimated market size and forecast in USD million) for the
period 2015 to 2025.
Section 8:
Market Size and
Forecast - Marketed
Drugs by
Geographic Regions
Quantitative and qualitative analysis of marketed drugs in the
Antacids market (estimated market size and forecast in USD
million) by geographic regions for the period 2015 to 2025.
 Developed Regions (North America and Europe)
 Developing Regions (Asia-Pacific, Latin America and
Middle-East)
 Rest of the World (RoW)
Section 9:
Market Share
Analysis - Key
Players (2015 and
2025)
% value market share estimated and analyzed for top players of the
Antacids market for the year 2015 and forecasted for the year 2025.
Section 10:
Pipeline Analysis
Pipeline Analysis for the Antacids market:
 Phases Mapped:

3.  Discovery and Preclinical Phase
 Clinical Phase 1
 Clinical Phase 2
 Clinical Phase 3
 Data Points Covered:
 Number of pipeline in each phase
 Number of “new or first-in-class” molecules, “me-too” drugs
and “generic” drugs
 Number of companies and their comparative analysis
Section 11:
Company Profiles
Top 5 companies (current marketed drugs) and Top 3 Companies
(pipeline drugs) in the Antacids market profiled with following
parameters (tabular representation):
 Financials (total revenue and specific market revenues)
 Business Overview
 Product Review
 Major Consolidations (mergers and acquisitions, joint ventures,
partnerships and collaborations)
Section 12:
Sources and
Methodology
Tabular representation of principal secondary and primary sources
utilized and description of the detailed methodology and assumptions
adopted while estimating the Antacids market.